341 related articles for article (PubMed ID: 19240169)
1. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
3. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
Conforti A; Cipriani B; Peruzzi D; Dharmapuri S; Kandimalla ER; Agrawal S; Mori F; Ciliberto G; La Monica N; Aurisicchio L
Vaccine; 2010 Apr; 28(20):3522-30. PubMed ID: 20332048
[TBL] [Abstract][Full Text] [Related]
4. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
[TBL] [Abstract][Full Text] [Related]
5. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
6. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
7. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
8. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
9. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity.
Spadaro M; Ambrosino E; Iezzi M; Di Carlo E; Sacchetti P; Curcio C; Amici A; Wei WZ; Musiani P; Lollini PL; Cavallo F; Forni G
Clin Cancer Res; 2005 Mar; 11(5):1941-52. PubMed ID: 15756020
[TBL] [Abstract][Full Text] [Related]
10. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
12. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
14. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.
Rolla S; Ria F; Occhipinti S; Di Sante G; Iezzi M; Spadaro M; Nicolò C; Ambrosino E; Merighi IF; Musiani P; Forni G; Cavallo F
J Immunol; 2010 Jun; 184(11):6124-32. PubMed ID: 20435927
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice.
Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A
Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624
[TBL] [Abstract][Full Text] [Related]
18. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model.
Dharmapuri S; Aurisicchio L; Biondo A; Welsh N; Ciliberto G; La Monica N
Hum Gene Ther; 2009 Jun; 20(6):589-97. PubMed ID: 19222350
[TBL] [Abstract][Full Text] [Related]
19. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
Rovero S; Boggio K; Di Carlo E; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G
Gene Ther; 2001 Mar; 8(6):447-52. PubMed ID: 11313823
[TBL] [Abstract][Full Text] [Related]
20. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
